- Home
- IMNM vs NSIT Comparison
IMNM vs NSIT Comparison
Compare IMNM & NSIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMNM | NSIT |
|---|---|---|
| Founded | 2006 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | IMNM | NSIT |
|---|---|---|
| Price | $22.03 | $100.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $32.80 | ★ $116.25 |
| AVG Volume (30 Days) | ★ 915.1K | 608.7K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.40 | N/A |
| EPS | N/A | ★ 0.97 |
| Revenue | $6,941,000.00 | ★ $8,247,180,000.00 |
| Revenue This Year | N/A | $3.79 |
| Revenue Next Year | $1,127.34 | $2.16 |
| P/E Ratio | ★ N/A | $100.59 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.96 | $63.62 |
| 52 Week High | $27.65 | $148.36 |
Technical Indicators
Market Signals| Indicator | IMNM | NSIT |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 78.98 |
| Support Level | $19.23 | $79.24 |
| Resistance Level | $23.24 | $111.54 |
| Average True Range (ATR) | 1.27 | 5.54 |
| MACD | -0.05 | 1.75 |
| Stochastic Oscillator | 55.07 | 96.75 |
Price Performance
Historical ComparisonAbout IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
About NSIT Insight Enterprises Inc.
Insight Enterprises Inc is a Fortune IT provider engaged in helping businesses of all sizes, large enterprises, government agencies, schools, and healthcare organizations. The company has three geographic operating segments: North America, EMEA, and APAC. It generates maximum revenue from the North America segment. The company provides digital workplace, cloud/data center transformation, IT modernization, Cyber Security and supply chain optimization solutions and services.